

THE CORRECT ANSWER IS INDICATED WITH YELLOW HIGHLIGHTING.

- 1. Which of the following statements is true regarding the CDK4/6 inhibitor abemaciclib?**
 - a. It has demonstrated activity in combination with endocrine therapy for patients with early breast cancer
 - b. It does not demonstrate single-agent activity
 - c. It is administered on a continuous schedule
 - d. All of the above
 - e. Both a and c**
 - f. Both b and c
- 2. The Phase III TAILORx trial demonstrated which of the following results in regard to the primary (invasive disease-free survival) and secondary (distant relapse-free interval) endpoints for patients with hormone receptor (HR)-positive, HER2-negative, node-negative breast cancer and a Recurrence Score® of 11 to 25?**
 - a. Inferiority of chemoendocrine therapy to endocrine therapy alone
 - b. Noninferiority of chemoendocrine therapy to endocrine therapy alone**
 - c. Superiority of chemoendocrine therapy to endocrine therapy alone
- 3. Which of the following statements is true in regard to the activity of alpelisib in patients HR-positive, HER2-negative advanced breast cancer?**
 - a. Alpelisib is not effective in patients who have previously received a CDK4/6 inhibitor
 - b. Alpelisib is effective only in patients who have previously received a CDK4/6 inhibitor
 - c. Alpelisib is effective irrespective of prior exposure to a CDK4/6 inhibitor**
- 4. Which of the following categories best characterizes the mechanism of action of the novel agent capivasertib?**
 - a. AKT inhibitor**
 - b. Aromatase inhibitor
 - c. Bcl-2 inhibitor
 - d. CDK4/6 inhibitor